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A B S T R A C T
Facioscapulohumeral dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array on chromosome 4q resulting in sporadic misexpression of the
transcription factor DUX4 in skeletal muscle tissue. In ~4% of families, de novo D4Z4 contractions occur after fertilization resulting in somatic mosaicism with control
and FSHD1 cell populations present within the same patient. Reprogramming of mosaic ﬁbroblasts from two FSHD1 patients into human induced pluripotent stem
cells (hiPSCs) generated genetically matched control and FSHD1 hiPSC lines. All hiPSC lines contained a normal karyotype, expressed pluripotency genes and
diﬀerentiated into cells from the three germ layers.
Resource utility
The newly generated genetically matched hiPSC lines from the two
mosaic FSHD1 patients are useful for disease modelling, next genera-
tion sequencing and drug testing.
Resource details
Facioscapulohumeral dystrophy type 1 (FSHD1) is caused by a
contraction of the D4Z4 macrosatellite repeat array located on chro-
mosome 4q. Healthy individuals have a D4Z4 repeat array size of
8–100 units, while patients with FSHD1 carry a contracted repeat of
1–10 units (van der Maarel et al., 2012). A D4Z4 repeat array con-
traction causes sporadic DUX4 misexpression in skeletal muscle leading
to muscle weakness and wasting in patients. In some families (4%) de
novo contractions of the D4Z4 repeat array occur post-fertilization re-
sulting in a mosaicism with healthy and FSHD1 cell populations present
within a single individual (Lemmers et al., 2004). With the repro-
gramming of mosaic ﬁbroblasts into clonal hiPSC colonies it is possible
to separate cell populations and to generate control and disease hiPSC
lines with an identical genetic background. We selected two mosaic
FSHD1 ﬁbroblast lines with a balanced ratio of control and FSHD1 cell
populations and reprogrammed the mosaic ﬁbroblasts into hiPSCs using
synthetic RNA (Yoshioka et al., 2013). Single colonies were picked and
analyzed for D4Z4 repeat array size using pulsed ﬁeld gel electro-
phoresis followed by Southern blot analysis (Lemmers, 2017). We de-
tected a contracted D4Z4 repeat array in 33% and 25% of hiPSC clones
generated from patient 1 and patient 2, respectively (data not shown).
We next selected one control and one FSHD1 line from each patient for
complete characterization (Tables 1 and 2). In 0162-FSHD04 and 0163-
FSHD04 we detected the FSHD1-sized D4Z4 repeat array, while in
0162-CTRL05 and 0163-CTRL05 we detected the normal-sized D4Z4
repeat array conﬁrming the successful separation of control and FSHD1
cell populations after reprogramming (Fig. 1A). All lines showed a ty-
pical hiPSC morphology (Fig. 1B) and were negative for mycoplasma
(Supplementary Fig. S1A). Immunoﬂuorescence analysis of plur-
ipotency genes revealed that all lines expressed OCT3/4, NANOG and
SSEA4 (Fig. 1C). Quantiﬁcation of the expression levels of OCT4, SOX2
and NANOG in 0162 and 0163 lines showed a comparable expression to
control hiPSC line 114–1 which was previously published (Buijsen
et al., 2018). All hiPSC lines in this study showed a similar expression
level of pluripotency genes between lines and patients, while the ﬁ-
broblasts from which the hiPSC lines originated demonstrated no ex-
pression (Fig. 1D). We next analyzed the hiPSC lines for unbalanced
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chromosomal abnormalities using a Global Screening Array (GSA v1
Illumina Inc.) carrying probes for 700 k single nucleotide polymorph-
isms (SNPs). We quantiﬁed for each SNP the relative signal intensities
and detected no copy number abnormalities (resolution: ~50 kb)
(Fig. 1E). Comparing 700 k SNPs of hiPSC lines with the original ﬁ-
broblasts showed an overlap of at least> 99,9% (Supplementary Fig.
S1B) demonstrating that patient 1 ﬁbroblasts were identical to 0162-
CTRL05 and 0162-FSHD04 and that patient 2 ﬁbroblasts were identical
to 0163-CTRL05 and 0163-FSHD04. Finally, we induced spontaneous
diﬀerentiation and determined the formation of cells from the three
germ layers. In all hiPSC lines we detected cells positive for Vimentin
(mesoderm), PAX6 (ectoderm) and FOXA2 (endoderm) showing the
capacity of the hiPSCs to diﬀerentiate towards cells from the three germ
layers (Fig. 1F).
Materials and methods
Ethical statement
Fibroblasts previously obtained from anonymized human skin
biopsies from individuals with FSHD1 were provided by the Fields
Center for FSHD Research biorepository and utilized in this study to
create hiPSC lines (RSRB00059324). This study was performed in ac-
cordance and approval of the LUMC scientiﬁc ethical committee.
Generation of hiPSCs
Fibroblasts were reprogrammed using synthetic RNA with the
ReproRNA™-OKSGM kit (STEMCELL Technologies) according to the
manufacturer's instructions. After reprogramming single colonies were
picked and expanded in TESR-E8 medium (STEMCELL Technologies).
Conﬂuent cultures were passaged with gentle cell dissociation reagent
on Vitronectin XF coated plates (STEMCELL Technologies).
Pulsed ﬁeld electrophoresis and southern blot analysis
D4Z4 repeat array size was determined with pulsed ﬁeld gel
electrophoresis followed by Southern blot analysis according to a pro-
tocol previously established in our laboratory (Lemmers, 2017). For
each hiPSC line, an agarose block containing 1×106 hiPSCs was di-
gested with EcoRI and HindIII restriction enzymes (Thermo Scientiﬁc).
The D4Z4 repeat array was detected with a radioactive labelled p13E-
11 DNA probe recognizing the p13E-11 region proximal of the D4Z4
repeat array. The D4Z4 hybridization pattern at the ancestral ﬁbro-
blasts served as a reference.
Spontaneous diﬀerentiation
hiPSCs were passaged on glass coverslips coated with Matrigel
(Corning) and spontaneous diﬀerentiation was induced with the
STEMdiﬀ™ Trilineage Diﬀerentiation Kit (STEMCELL Technologies).
After 5 days (endoderm and mesoderm) or 7 days (ectoderm) cells were
ﬁxed with 2% paraformaldehyde (PFA) for 30min at room temperature
and used for immunoﬂuorescence staining.
Immunoﬂuorescence staining
PFA-ﬁxed hiPSCs on coverslips were permeabilized with 0.1%
Triton X-100, blocked for 1 h in 4% normal swine serum (NSS, DAKO)/
PBS, washed once with PBS and incubated for 1 h with primary anti-
bodies (Table 3) diluted in blocking buﬀer. Coverslips were next wa-
shed 3 times for 10min with washing buﬀer (0.05% Tween in PBS)
followed by an incubation step with secondary antibodies in blocking
buﬀer for 1 h. Finally, coverslips were washed 3 times for 10min with
washing buﬀer, incubated with DAPI (1:200, Thermo Scientiﬁc) in PBS
for 5min and imaged with a Leica TCS SP8 microscope.
RNA isolation and quantitative RT-PCR
RNA was extracted using the miRNeasy mini kit including a DNase I
treatment (Qiagen). 800 ng of RNA was next reverse transcribed using
the RevertAid™ H Minus First Strand cDNA Synthesis Kit (Thermo
Fisher). The resulting cDNA was diluted 50× and used in a qRT-PCR
reaction consisting of 7.5 μl SybrGreen (Bio-Rad) and 10 pmol of
Table 1
Summary of lines.
hiPSC line names Abbreviation in ﬁgures Gender Age Ethnicity Genotype of locus (# 4qA D4Z4 repeats) Disease
LUMC0162iCTRL05 0162-CTRL05 Male 53 Caucasian 45 Control
LUMC0162iFSHD04 0162-FSHD04 Male 53 Caucasian 3 FSHD1
LUMC0163iCTRL05 0163-CTRL05 Male 60 Caucasian 43 Control
LUMC0163iFSHD04 0163-FSHD04 Male 60 Caucasian 2 FSHD1
Table 2
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Brightﬁeld microscopy Normal morphology Fig. 1, panel B
Phenotype Qualitative analysis by
immunoﬂuorescence staining
Positive staining of pluripotency markers: OCT3/4,
NANOG and SSEA4
Fig. 1, panel C
Quantitative analysis by RT-qPCR Expression of pluripotency markers OCT4, SOX2 and
NANOG
Fig. 1, panel D
Genotype GSAMD24 v1 Illumina Inﬁnium SNP array
700 k
CNV report resolution 50 kb: No major copy number
variations or allelic changes
Fig. 1, panel E
Identity GSAMD24 v1 Illumina Inﬁnium SNP array
700 k
GSA array Summarized data in Supplementary
Fig. S1, panel B
Fibroblasts and hiPSCs have > 99,99% identical SNPs Data available upon request
Mutation analysis (IF
APPLICABLE)
Pulsed ﬁeld gel electrophoresis / Southern
blot analysis
0162-CTRL05: D4Z4 4qA 155 kb (45 repeats) Fig. 1, panel A
0162-FSHD04: D4Z4 4qA 15 kb (3 repeats)
0163-CTRL05: D4Z4 4qA 147 kb (43 repeats)
0163-FSHD04: D4Z4 4qA 13 kb (2 repeats)
Microbiology and virology Mycoplasma Mycoplasma testing by luminescence: Negative Supplementary Fig. S1, panel A
Diﬀerentiation potential Qualitative analysis by
immunoﬂuorescence staining
Positive staining of germ layer markers Vimentin
(mesoderm), PAX6 (ectoderm) and FOXA2 (endoderm)
Fig. 1, panel F
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Fig 1. Characterization of hiPSC lines. (A) Detection of the D4Z4 repeat with pulsed ﬁeld gel electrophoresis and Southern blotting. Arrows indicate the FSHD1-sized
repeat (red) or the control-sized repeat (green). (B) Representative light microscope images of hiPSCs. (C) Immunoﬂuorescence staining of OCT3/4, NANOG, SSEA4.
Nuclei were stained with DAPI. (D) qRT-PCR analysis of OCT4, NANOG and SOX2 expression in primary ﬁbroblasts and generated hiPSCs. Data are normalized for
GUSB. (E) Analysis of the copy number of 700k single nucleotide polymorphisms using the Global Screening Array (GSA v1 Illumina Inc.).
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forward and reverse primers (Table 3). Reactions were analyzed on a
CFX 96 machine (Bio-Rad).
Genomic DNA isolation and global screening array
Genomic DNA was extracted using a standard high salt protocol
followed by puriﬁcation with the DNA Clean & Concentrator kit (Zymo
Research). 200 ng of genomic DNA was next loaded on a Global
Screening Array (GSA) (Illumina) according to the manufacturer's in-
structions. Generated GSA manifest ﬁles were analyzed with
GenomeStudio software and ﬁnal reports were visualized using Nexus
Discovery (BioDiscovery El Segundo).
Mycoplasma detection
Cultures were tested for mycoplasma with MycoAlert Mycoplasma
detection kit (Lonza, Walkersville, MD) according to the manufacturer's
instructions.
Key resource table
Unique stem cell lines ide-
ntiﬁer
LUMCi011-A
LUMCi011-B
LUMCi012-A
LUMCi012-B
Alternative names of stem
cell lines
LUMCi011-A: LUMC0162iCTRL05 and 0162-CTRL05
LUMCi011-B: LUMC0162iFSHD04 and 0162-FSHD04
LUMCi012-A: LUMC0163iCTRL05 and 0163-CTRL05
LUMCi012-B: LUMC0163iFSHD04 and 0163-FSHD04
Institution Leiden University Medical Center (LUMC), Leiden, The
Netherlands
Contact information of di-
stributor
Dr. J.C. de Greef, j.c.de_greef@lumc.nl
Type of cell lines hiPSCs
Origin Human
Cell source Skin ﬁbroblasts
Clonality Clonal
Method of reprogramming Non-integrating synthetic RNA
Multiline rationale Genetically matched control/disease
Gene modiﬁcation Yes
Type of modiﬁcation Heredity
Associated disease FSHD1
Gene/locus Patient1: 4qA, 4q35 D4Z4 repeats: 45 (control) / 3
(FSHD1)
Patient2: 4qA, 4q35 D4Z4 repeats: 43 (control) / 2
(FSHD1)
Method of modiﬁcation N/A
Name of transgene or re-
sistance
N/A
Inducible/constitutive sys-
tem
N/A
Date archived/stock date November 2018
Cell line repository/bank https://hpscreg.eu/cell-line/LUMCi011-A
https://hpscreg.eu/cell-line/LUMCi011-B
https://hpscreg.eu/cell-line/LUMCi012-A
https://hpscreg.eu/cell-line/LUMCi012-B
Ethical approval RSRB00059324, Research Subjects Review Board,
University of Rochester.
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